It’s do-or-die time on drug pricing when Congress returns to Washington in a few weeks.  That’s how stakeholders are viewing the whole messy effort to take major action to lower the high prices of prescription medicines in the United States — a top-polling worry among voters that President Trump has repeatedly promised to tackle.